DSUVIA (sufentanil) Drug Insights and U.S. Market Analysis, 2023-2032
30 janv. 2024 08h01 HE
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "United States DSUVIA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This extensive report...
ACRX SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ACRX
15 juin 2021 18h15 HE
|
The Rosen Law Firm PA
WHY: NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx...
Sufentanil (CAS 56030-54-7) Market Research Report 2012
21 nov. 2013 09h34 HE
|
Research and Markets
Dublin, Nov. 21, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/bwh6p3/sufentanil_cas)
has announced the addition of the "Sufentanil
(CAS 56030-54-7) Market...